Alane Barnes Sells 21,773 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider Alane Barnes sold 21,773 shares of the company’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.65, for a total transaction of $166,563.45. Following the transaction, the insider owned 398,751 shares of the company’s stock, valued at $3,050,445.15. This represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

BioCryst Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ BCRX traded down $0.08 during trading on Tuesday, hitting $7.53. The company had a trading volume of 2,139,545 shares, compared to its average volume of 4,025,963. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -150.60, a price-to-earnings-growth ratio of 0.71 and a beta of 0.91. The stock has a fifty day simple moving average of $7.18 and a two-hundred day simple moving average of $8.07. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The company had revenue of $159.40 million during the quarter, compared to analysts’ expectations of $162.91 million. During the same period in the prior year, the business posted ($0.07) earnings per share. The company’s quarterly revenue was up 36.1% compared to the same quarter last year. On average, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on BCRX shares. JMP Securities boosted their price target on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research report on Wednesday, October 15th. Citizens Jmp dropped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a report on Wednesday, November 5th. TD Cowen initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target on the stock. Cantor Fitzgerald upped their price objective on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. Finally, Needham & Company LLC decreased their target price on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Ten equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $19.50.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jump Financial LLC raised its stake in shares of BioCryst Pharmaceuticals by 805.0% during the 2nd quarter. Jump Financial LLC now owns 1,347,112 shares of the biotechnology company’s stock worth $12,070,000 after buying an additional 1,198,263 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in BioCryst Pharmaceuticals by 48.7% during the second quarter. JPMorgan Chase & Co. now owns 1,584,206 shares of the biotechnology company’s stock worth $14,194,000 after acquiring an additional 518,623 shares during the period. Russell Investments Group Ltd. raised its position in BioCryst Pharmaceuticals by 326.1% in the second quarter. Russell Investments Group Ltd. now owns 440,249 shares of the biotechnology company’s stock worth $3,945,000 after acquiring an additional 336,920 shares in the last quarter. Assenagon Asset Management S.A. raised its position in BioCryst Pharmaceuticals by 25,631.2% in the second quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock worth $32,441,000 after acquiring an additional 3,606,566 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in BioCryst Pharmaceuticals by 2,103.7% in the second quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after acquiring an additional 4,084,403 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.